Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
about
Invasive Bladder Cancer: Genomic Insights and Therapeutic PromiseThe Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivoTumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
P2860
Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@ast
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@en
type
label
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@ast
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@en
prefLabel
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@ast
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@en
P2093
P2860
P1476
Dovitinib: rationale, preclini ...... lial carcinoma of the bladder.
@en
P2093
Joseph Chin
Khurram M Siddiqui
Michele Billia
P2860
P304
P356
10.1517/13543784.2014.966900
P407
P577
2014-10-04T00:00:00Z